company background image
LCTX

Lineage Cell Therapeutics NYSEAM:LCTX Stock Report

Last Price

US$1.57

Market Cap

US$266.5m

7D

14.6%

1Y

-42.9%

Updated

03 Jul, 2022

Data

Company Financials +
LCTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

LCTX Stock Overview

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally.

Lineage Cell Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lineage Cell Therapeutics
Historical stock prices
Current Share PriceUS$1.57
52 Week HighUS$2.81
52 Week LowUS$1.10
Beta1.89
1 Month Change12.14%
3 Month Change0%
1 Year Change-42.91%
3 Year Change41.44%
5 Year Change-49.84%
Change since IPO-54.05%

Recent News & Updates

Shareholder Returns

LCTXUS BiotechsUS Market
7D14.6%0.2%-2.2%
1Y-42.9%-25.1%-21.2%

Return vs Industry: LCTX underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: LCTX underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is LCTX's price volatile compared to industry and market?
LCTX volatility
LCTX Average Weekly Movement10.8%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.3%

Stable Share Price: LCTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: LCTX's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199059Brian Culleyhttps://www.lineagecell.com

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product.

Lineage Cell Therapeutics Fundamentals Summary

How do Lineage Cell Therapeutics's earnings and revenue compare to its market cap?
LCTX fundamental statistics
Market CapUS$266.47m
Earnings (TTM)-US$48.69m
Revenue (TTM)US$9.19m

29.0x

P/S Ratio

-5.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LCTX income statement (TTM)
RevenueUS$9.19m
Cost of RevenueUS$1.49m
Gross ProfitUS$7.70m
Other ExpensesUS$56.39m
Earnings-US$48.69m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.29
Gross Margin83.78%
Net Profit Margin-529.99%
Debt/Equity Ratio0%

How did LCTX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is LCTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LCTX?

Other financial metrics that can be useful for relative valuation.

LCTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue20.4x
Enterprise Value/EBITDA-4.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does LCTX's PS Ratio compare to its peers?

LCTX PS Ratio vs Peers
The above table shows the PS ratio for LCTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average23.5x
STRO Sutro Biopharma
4.6x36.8%US$246.4m
EPZM Epizyme
6.3x39.1%US$244.0m
ANIK Anika Therapeutics
2.2x7.9%US$327.4m
AADI Aadi Bioscience
80.9x69.3%US$267.4m
LCTX Lineage Cell Therapeutics
29x52.1%US$266.5m

Price-To-Sales vs Peers: LCTX is expensive based on its Price-To-Sales Ratio (29x) compared to the peer average (23.5x).


Price to Earnings Ratio vs Industry

How does LCTX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: LCTX is expensive based on its Price-To-Sales Ratio (29x) compared to the US Biotechs industry average (13.2x)


Price to Sales Ratio vs Fair Ratio

What is LCTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LCTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio29x
Fair PS Ratio15.4x

Price-To-Sales vs Fair Ratio: LCTX is expensive based on its Price-To-Sales Ratio (29x) compared to the estimated Fair Price-To-Sales Ratio (15.4x).


Share Price vs Fair Value

What is the Fair Price of LCTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LCTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LCTX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LCTX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Lineage Cell Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


48.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LCTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LCTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LCTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LCTX's revenue (52.1% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: LCTX's revenue (52.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LCTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Lineage Cell Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-17.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LCTX is currently unprofitable.

Growing Profit Margin: LCTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LCTX is unprofitable, and losses have increased over the past 5 years at a rate of 17.8% per year.

Accelerating Growth: Unable to compare LCTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LCTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).


Return on Equity

High ROE: LCTX has a negative Return on Equity (-57.4%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Lineage Cell Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LCTX's short term assets ($81.9M) exceed its short term liabilities ($24.6M).

Long Term Liabilities: LCTX's short term assets ($81.9M) exceed its long term liabilities ($34.7M).


Debt to Equity History and Analysis

Debt Level: LCTX is debt free.

Reducing Debt: LCTX has no debt compared to 5 years ago when its debt to equity ratio was 1.1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable LCTX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: LCTX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 18.5% per year.


Discover healthy companies

Dividend

What is Lineage Cell Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LCTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LCTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LCTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LCTX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LCTX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Brian Culley (51 yo)

3.83yrs

Tenure

US$2,754,475

Compensation

Mr. Brian M. Culley, M.A., M.B.A., served as Interim Chief Financial Officer at Lineage Cell Therapeutics, Inc. since January 20, 2021 until June 21, 2021. He serves as Chief Executive Officer at Artemis T...


CEO Compensation Analysis

Compensation vs Market: Brian's total compensation ($USD2.75M) is above average for companies of similar size in the US market ($USD1.83M).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: LCTX's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: LCTX's board of directors are considered experienced (7.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.


Top Shareholders

Company Information

Lineage Cell Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Lineage Cell Therapeutics, Inc.
  • Ticker: LCTX
  • Exchange: NYSEAM
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$266.472m
  • Shares outstanding: 169.73m
  • Website: https://www.lineagecell.com

Number of Employees


Location

  • Lineage Cell Therapeutics, Inc.
  • 2173 Salk Avenue
  • Suite 200
  • Carlsbad
  • California
  • 92008
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.